Our Custom mRNA-based B Cell Reprogramming Service leverages B cell plasticity—driven by deleting master regulators like Pax5 and expressing TFs such as C/EBPα—to transdifferentiate B cells into macrophages, erythroid cells, etc. We use stable modified mRNA for transient TF expression, enabling rapid, genome-unaltered cell fate conversion.
Offering integration-free technology and high-efficiency delivery, we accelerate patient-derived immune cell engineering. Our targeted solutions overcome B cell plasticity and reprogramming challenges, delivering high-purity functional cells for therapeutics or research, with safer, faster paths to clinical candidates.
Discover How We Can Help - Request a Consultation
Fig.1 The dual characteristics of B cells in the tumor microenvironment of cancer. Its anti-tumor properties can be used to enhance the targets of immunotherapy.1
B cell reprogramming hinges on overriding the established transcriptional programs maintained by key factors like Pax5 and EBF1. By transiently delivering specific, powerful TFs via mRNA, we induce a rapid epigenetic reset. For instance, delivering C/EBPα causes the silencing of B-lymphocyte genes and the activation of macrophage-specific genes, resulting in the complete and highly efficient conversion of the cell's identity. This transdifferentiation is distinct from generating iPSCs (though possible), as it often results in a direct switch to a committed lineage, preserving specific features like the original Immunoglobulin (Ig) gene rearrangements, which is invaluable for certain immunological studies.
The core advantage lies in bypassing the safety and complexity challenges of traditional DNA- or retrovirus-based methods.
The functional cells generated through this service have vast potential in:
We offer a comprehensive, streamlined, and scalable process designed for maximum transparency and efficiency, ensuring high-quality, functional cell outputs tailored to your specific research needs.
Conduct custom sequence design, codon optimization, incorporation of modified nucleotides (e.g., Pseudouridine, N6-Methyladenosine), and 5' capping (e.g., ARCA).
Design and synthesize customized lipid formulations, including Lipid Nanoparticles (LNPs), for mRNA payload delivery.
Optimize transfection parameters (dose, timing, vehicle ratio) tailored to specific B cell source material.
Maintain sustained culture in specialized media under defined conditions, withdrawing B cell survival factors and adding lineage-specific factors (e.g., macrophage growth factors).
Sort or select converted cells, followed by rigorous QC for viability, purity, and functional validation (e.g., phagocytosis assays for macrophages).
Estimated Timeframe: 6–12 weeks, depending on the complexity of the target lineage and the required cell output scale.
Creative Biolabs is a true one-stop solution for Custom mRNA-based B-cell reprogramming Services. We recognize that every cell engineering project is unique, requiring meticulous customization. Our advanced capabilities ensure seamless transition from initial concept to validated, functional cell output.
One-Stop Reprogramming Solution
Comprehensive service covering custom mRNA design, synthesis, optimization, LNP formulation, and final functional validation.
Custom Transcription Factor Combinations
Test and implement specialized TF cocktails (e.g., C/EBPα, GATA-1, SCL, OKSM) tailored to generate target cell lineages.
Advanced mRNA Engineering & Optimization
Custom mRNA modifications (e.g., Pseudouridine, ARCA capping) ensure maximum stability and translational efficiency in primary B cells.
Proprietary Delivery System Development
Custom LNPs/lipoplexes engineered for optimized B cell transfection, overcoming immune cell delivery challenges.
Rigorous Quality-by-Design (QbD) Protocols
Strict PAT and quality systems throughout culture/reprogramming to ensure reproducibility and functional fidelity.
Full Functional Characterization
Custom functional assays (e.g., phagocytosis, cytokine secretion) validate reprogrammed cells' phenotype and function.
Scalable Output
Seamless scale-up from small feasibility studies to pre-clinical/large-scale in vitro screening production volumes.
Experience the Creative Biolabs Advantage - Get a Quote Today
The primary advantage of mRNA over lentivirus is safety and speed. While lentivirus offers permanent gene integration, our mRNA method is integration-free, eliminating the risk of insertional mutagenesis, which is often a major regulatory hurdle. Additionally, the high efficiency of mRNA allows for visible lineage conversion in just a few days, dramatically speeding up your timeline.
We strive for the highest purity possible. Our process is optimized for high conversion rates, often resulting in yields far exceeding traditional methods. Validation is achieved using multiple methods, including flow cytometry for specific surface markers (e.g., Mac-1, F4/80, CD11b) and functional assays (e.g., phagocytosis).
Yes. RNA reprogramming is inherently more efficient than other methods, requiring fewer starting cells to achieve a successful outcome. We specialize in optimizing protocols for limited or difficult-to-reprogram primary cell sources, which is a major benefit for rare patient samples.
Our expertise includes the development of custom delivery vehicles like LNPs that are engineered for high transfection efficiency. While our standard service focuses on ex vivo reprogramming, we offer advanced LNP development services tailored toward specific cell tropism, which can be adapted for in vivo applications.
We use proprietary modifications in the mRNA backbone. This includes incorporating Pseudouridine to reduce immunogenicity and enhancing the 5' end with specialized caps like ARCA, ensuring the mRNA remains stable and robustly translated by the cell's machinery. This engineering is critical for the transient, high-level expression necessary for a successful lineage switch.
Creative Biolabs offers an industry-leading, integration-free platform for high-efficiency B lymphocyte transdifferentiation. Combining expertise in master transcription factors (e.g., C/EBPα), cutting-edge modified mRNA technology, and custom LNP delivery systems, we deliver safe, rapid, scalable solutions for generating functional patient-derived cells critical for research and therapeutic development.
Contact Our Team for More Information and to Discuss Your Project
Reference
